Fennec Pharmaceuticals (FENC) CSO gains 156 vested shares in Form 4 filing

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. Chief Strategy Officer Christiana Marie Cioffi reported a small share award under the company’s equity compensation. On May 31, 2026, she acquired 156 common shares at $0.00 per share, representing shares released from restriction from an award granted on March 28, 2025. Following this vesting-related acquisition, she directly holds 24,176 common shares, indicating a routine, compensation-driven increase in her ownership rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cioffi Christiana Marie

Role Chief Strategy Officer

Type	Security	Shares	Price	Value
Grant/Award	Common shares	156	$0.00	--

Holdings After Transaction: Common shares — 24,176 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares acquired: 156 common shares Transaction price: $0.00 per share Post-transaction holdings: 24,176 common shares +1 more

4 metrics

Shares acquired 156 common shares Grant/award acquisition on May 31, 2026

Transaction price $0.00 per share Equity award release from restriction

Post-transaction holdings 24,176 common shares Direct ownership after May 31, 2026 transaction

Award grant date March 28, 2025 Original date of shares later released from restriction

Key Terms

Grant, award, or other acquisition, Common shares, released from restriction

3 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common shares financial

"security_title: Common shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

released from restriction financial

"Represents shares released from restriction from shares awarded 3/28/2025."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cioffi Christiana Marie

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Strategy Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	05/31/2026		A		156	A	$0	24,176	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 3/28/2025.

	/s/ Christiana Cioffi	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fennec Pharmaceuticals (FENC) report for Christiana Marie Cioffi?

Fennec Pharmaceuticals reported that Chief Strategy Officer Christiana Marie Cioffi acquired 156 common shares. The shares were received as part of an equity award, not through an open-market purchase or sale.

How many Fennec Pharmaceuticals (FENC) shares did Christiana Marie Cioffi acquire in this Form 4?

Christiana Marie Cioffi acquired 156 common shares of Fennec Pharmaceuticals. These shares were released from restriction under a prior award dated March 28, 2025, and carried a transaction price of $0.00 per share.

What is Christiana Marie Cioffi’s total Fennec Pharmaceuticals (FENC) shareholding after this transaction?

After the transaction, Christiana Marie Cioffi directly holds 24,176 common shares of Fennec Pharmaceuticals. This total reflects the addition of 156 vested shares from a previously granted equity award.

Was the Fennec Pharmaceuticals (FENC) Form 4 transaction an open-market buy or sell?

The Form 4 transaction was not an open-market buy or sell. It reflects a grant or award acquisition, with 156 common shares released from restriction as part of compensation and recorded at a price of $0.00 per share.

What does the footnote in the Fennec Pharmaceuticals (FENC) Form 4 filing explain?

The footnote explains that the 156 shares represent shares released from restriction from shares awarded on March 28, 2025. This clarifies the transaction as vesting of a prior equity award rather than a new market transaction.